Acura Pharmaceuticals IncACUR- 行情中心数据中心财经频道 - -- 今开: - 最高: - 成交量: - 买入价: - 内盘: - 振幅: - 昨收: - 最低: - 成交额: - 卖出价: - 外盘: - 量比: - 股市备忘公告大全停牌概览报刊头条晚间快讯盈利预测股票账户股东人数券商晨会基金持仓社保持仓...
On March 17, 2017, Acura entered into a licensing agreement with MainPointe Pharmaceuticals granting them the right to exclusively market NEXAFED® and NEXAFED® Sinus Pressure + Pain in the United States and Canada. NEXAFED® Nasal Decongestant Tablets NEXAFED® Nasal Decongestant (pseudoephe...
Acura Pharmaceuticals Inc(ACUR)股吧,股民朋友可以在这里畅所欲言,分析讨论股票名的最新动态。东方财富股吧,专业的股票论坛社区。
Acura Pharmaceuticals, Inc. is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multi...
Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935...
--Acura Pharmaceuticals, Inc. today announced an amendment to its License, Development and Commercialization Agreement regarding Acura’ s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC to extend the FDA Acceptance Date for
Acura Pharmaceuticals Inc. (ACUR) Historical NOCP 5D 1月 3月 6月 1年 Nasdaq Historical NOCP is available only for Nasdaq Symbols. *Today’s High/Low is only updated during regular trading hours; and does not include trades occurring in pre-market or after-hours.纳斯达克官方收盘价 (NOCP)...
Acura-PharmaceuticalsKing-PharmaceuticalsOxycodone/niacin, therapeutic usePostoperative-pain, treatmentTrial-result-clinical
This Code of Ethics (the “Code”) is established pursuant to Section 406 of the Sarbanes-Oxley Act of 2002, which requires that the Acura Pharmaceuticals, Inc. (the “Company”) establish a code of ethics to apply to the Company’s principal executive officer, principal financial officer, ...
Acura Pharmaceuticals - The specialty pharmaceutical company said its painkiller drug made with abuse-deterrent technology did not show statistically significant results in reducing likability among users. Shares plunged in extended-hours trading. Jones Lang LaSalle - The real-estate services company acqu...